United States Hereditary Angioedema Therapeutics Market to Grow with a CAGR of 7.12% through 2029
Rising
awareness and improved diagnosis is expected to drive the United States
Hereditary Angioedema Therapeutics Market in the forecast period.
According to TechSci
Research report, “United Kingdom Regenerative Agriculture Market – By Region, Competition, Forecast and Opportunities, 2029F”, the United States Hereditary Angioedema Therapeutics Market stood at
USD 846.80 million in 2023 and is anticipated to grow with a CAGR of 7.12% in
the forecast period, 2025-2029. Recent years have seen significant strides in
treating Hereditary Angioedema (HAE), a rare genetic disorder marked by
recurrent, severe swelling in various body parts. In the United States,
heightened awareness of HAE among healthcare professionals and the public has
led to improved diagnosis and expanded patient populations needing treatment.
Traditional therapies like C1 inhibitor replacement and bradykinin receptor
antagonists, while effective, had limitations. However, recent drug
developments, including subcutaneous and oral options, offer enhanced
convenience, fewer side effects, and improved patient experiences. The US FDA's
proactive evaluation and approval of breakthrough therapies, such as
lanadelumab (Takhzyro), have revolutionized HAE management. These medications
provide long-lasting prevention of attacks, reducing administration frequency
and improving disease control, leading to fewer hospitalizations and better
patient outcomes.
Browse
over XX market data Figures spread through XX Pages and an in-depth TOC
on "United
States Hereditary Angioedema Therapeutics Market.”
The HAE therapeutics market
has shifted towards a more patient-centric approach, acknowledging the specific
requirements of individuals with HAE and customizing treatments to enhance
their quality of life. This strategy extends beyond the creation of more
convenient therapies and encompasses patient support initiatives, educational
materials, and advocacy campaigns aimed at empowering patients and their
families. By ensuring that patients are educated and involved in managing their
condition, these endeavors are crucial for achieving sustainable long-term
outcomes.
The United States
Hereditary Angioedema Therapeutics Market is segmented into treatment, route of administration, end-use, regional distribution, and
company.
Based on the end use, Prophylaxis segment emerged as
the dominant segment in the United States market for United States Hereditary
Angioedema Therapeutics Market in 2023. This is primarily due
to the increasing recognition of the importance of preventive measures in
managing HAE. Prophylactic treatments aim to minimize the frequency and
severity of attacks, thus improving patients' overall quality of life and
reducing the need for emergency interventions. Advancements in therapeutic
options, such as long-acting monoclonal antibodies, have made prophylactic
regimens more attractive and feasible for patients, further driving the
dominance of this segment in the market.
Based on region, Mid-west segment emerged as the
dominant segment in the United States market for United States Hereditary
Angioedema Therapeutics Market in 2023. This
is because the region hosts a substantial patient population, including those
requiring specialized HAE care, leading to a heightened demand for
therapeutics. The presence of renowned treatment centers and experts in the
Midwest attracts patients seeking advanced care. Several pharmaceutical
companies with a focus on rare diseases, including HAE, are headquartered or
have a significant presence in the Midwest. This concentration fosters
research, development, and commercialization efforts, driving the market's
growth in the region.
Major
companies operating in United States Hereditary Angioedema Therapeutics
Market are:
- BioCryst
Pharmaceuticals, Inc.
- Ionis Pharmaceuticals,
Inc.
- Seqirus Pty Ltd. (CSL Limited)
- Attune Pharmaceuticals, Inc.
- Adverum Biotechnologies,
Inc.
- KalVista Pharmaceuticals, Inc.
- Takeda Pharmaceutical
Company Limited
- Pharming Healthcare N.V.
- Sanofi AG
- Cipla Ltd.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“The United States
Hereditary Angioedema Therapeutics (HAE) market is primed for notable expansion
in the foreseeable future. Sustained research and development endeavors are
continually yielding novel therapies that boast enhanced efficacy and
patient-friendliness. From advanced monoclonal antibodies to oral medications
and prophylactic treatments, HAE patients now have a diverse range of options
for managing their condition. The heightened awareness, early diagnosis, and
genetic testing are refining the detection of HAE cases, facilitating prompt
intervention and tailored treatment strategies. Embracing a patient-centered
approach is increasingly prevalent, nurturing a climate of empowerment and
self-care among individuals grappling with HAE” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“United States
Hereditary Angioedema Therapeutics Market Segmented By Treatment (C1-esterase
inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others), By
Route of Administration (Intravenous, Subcutaneous, Oral), By End-use
(Prophylaxis, On-demand) Region and Competition, Opportunity, and Forecast, 2019-2029F”, has evaluated the future growth potential
of United States Hereditary Angioedema Therapeutics Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in United States Hereditary Angioedema
Therapeutics Market.
Contact
TechSci Research LLC
420 Lexington Avenue,
Suite 300,
New York, United
States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com